Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...

Sun Pharmaceutical Industries also rose by 5.51 per cent to settle at Rs 1,078.55. The stock was the top gainer among the 30-Sensex scrips.

Sun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.

The central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, t...

FTC has passed its final order settling charges that Sun Pharma's $4 billion deal to acquire Ranbaxy Laboratories could result in unfair bu...

Asked by CCI to divest seven products, drug makers Sun Pharmaceutical and Ranbaxy today said they will comply with the conditions put forth...

The drug maker also plans to draw up detailed cross-selling plans for each state, according to industry consultants familiar with the matte...

The CCI today said the major issue is whether the Sun-Ranbaxy deal would result in high market concentration of certain molecules.

Since 2011, CCI has cleared some 165 deals, including 46 in 2013 and more than 30 so far this year, according to data available on its webs...

Sun Pharma said it had "no access to non-public information of Ranbaxy" when its unit Silverstreet bought shares in Ranbaxy.

Shares of Ranbaxy, which is majority-owned by Japan’s Daiichi-Sankyo, saw an unusual increase in price and turnover during six trading days...

Sun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...

An investor who is really confident that the deal will go through can buy Ranbaxy shares and pocket the difference when the merger is compl...

Sun and their Japanese counterparts met for the first time as recently as the third week of March. A final agreement was in place by the en...

Shares of Sun Pharma surged 2.68 per cent or Rs 15.35 to close at Rs 587.25 as the all-share deal’s swap ratio is seen to favour investors ...

The Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.

Sun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market ...